`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`MYLAN INSTITUTIONAL LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-00324
`Patent 8,114,833
`______________
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION PRO HAC
`VICE OF RYAN P. JOHNSON UNDER 37 C.F.R. § 42.10(c)
`
`
`
`IPR2020-00324
`Patent 8,114,833
`
`I.
`
`STATEMENT OF PRECISE RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. § 42.10(c), as authorized by the Board’s Notice of
`
`Filing Date Accorded mailed December 30, 2019 (Paper 3), and in accordance with
`
`the Board’s Order, Paper 7 in Case IPR2013-00639, Patent Owner Novo Nordisk
`
`A/S (“Patent Owner”) requests that the Board admit Ryan P. Johnson pro hac vice
`
`in this proceeding. Counsel for Petitioner Mylan Institutional LLC (“Petitioner”)
`
`has informed counsel for Patent Owner that Petitioner does not oppose this Motion.
`
`II.
`
`STATEMENT OF FACTS SHOWING GOOD CAUSE FOR THE
`BOARD TO RECOGNIZE COUNSEL PRO HAC VICE IN THE
`PROCEEDING
`
`Under 37 C.F.R. § 42.10(c), the Board “may recognize counsel pro hac vice
`
`during a proceeding upon a showing of good cause, subject to the condition that
`
`lead counsel be a registered practitioner and to any other conditions as the Board
`
`may impose. For example, where the lead counsel is a registered practitioner, a
`
`motion to appear pro hac vice by counsel who is not a registered practitioner may
`
`be granted upon showing that counsel is an experienced litigating attorney and has
`
`an established familiarity with the subject matter at issue in the proceeding.”
`
`The facts, supported by the attached Declaration of Ryan P. Johnson in
`
`Support of Patent Owner’s Motion for Admission Pro Hac Vice (EX2001)
`
`establish good cause to admit Mr. Johnson pro hac vice in this proceeding.
`
`1
`
`
`
`1. Lead counsel, Jeffrey Oelke, is a registered practitioner (Reg. No.
`
`IPR2020-00324
`Patent 8,114,833
`
`37,409).
`
`2. Counsel for Patent Owner contacted counsel for Petitioner, who
`
`indicated that Petitioner did not plan to oppose Mr. Johnson’s admission pro hac
`
`vice.
`
`3. Counsel, Ryan P. Johnson, is an experienced litigating attorney with
`
`over twelve years in private practice and substantial experience with patent
`
`litigation. EX2001 at ¶ 9. Mr. Johnson has been counsel in patent infringement
`
`matters in multiple U.S. District Courts, the U.S. Court of Appeals for the Federal
`
`Circuit, and the U.S. Court of Appeals for the Fourth Circuit. Id. Mr. Johnson is a
`
`member in good standing of the State Bars of New York and Connecticut. Id. at ¶
`
`1. He is also admitted to practice in the United States District Court for the Southern
`
`District of New York, the United States District Court for the Eastern District of
`
`New York, the United States Court of Appeals for the Federal Circuit, and the United
`
`States District Court for the Fourth Circuit. Id. He has had no suspensions or
`
`disbarments from practice, no application for admission to practice denied, nor any
`
`sanctions or contempt citations. Id. at ¶¶ 2-4.
`
`4. Within the past four years, Mr. Johnson has thrice applied for and been
`
`granted permission to practice before this Board pro hac vice in the following
`
`matters: Laboratoire Francais Du Fractionnement et des Biotechnologies S.A. v.
`
`2
`
`
`
`IPR2020-00324
`Patent 8,114,833
`
`Novo Nordisk Healthcare AG, IPR2017-00028 (Paper No. 36); Pfizer Inc. v. Biogen,
`
`Inc., (Paper No. 54); and Pharmacosmos A/S v. American Regent, Inc., (Paper No.
`
`9). Id. at ¶ 7. Mr. Johnson also has a Motion for Pro Hac Vice pending before the
`
`Board. See Pharmacosmos A/S v. Luitpold Pharmaceuticals, Inc., (Paper No. 67).
`
`Id.
`
`5. Mr. Johnson has familiarity with the subject matter and patent-at-issue
`
`in this proceeding, U.S. Patent No. 8,114,833 (the “’833 patent”), including its
`
`prosecution history and the scientific field to which the ’833 patent is addressed. Id.
`
`at ¶ 8. Mr. Johnson has served and is presently serving as counsel for Patent Owner
`
`in district court litigation involving the ’833 patent. Id.
`
`6. Mr. Johnson has read and will comply with the Office Patent Trial
`
`Practice Guide and updates thereto and the Board’s Rules for Practices for Trials set
`
`forth in part 42 of title 37 of the Code of Federal Regulations, and he agrees to be
`
`subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101
`
`et seq. and to disciplinary jurisdiction under 37 C.F.R. § 11.19(a). EX2001 at ¶¶ 5-
`
`6.
`
`III. STATEMENT OF REASONS FOR THE RELIEF REQUESTED
`
`The facts stated above, as supported by the Declaration of Ryan P. Johnson
`
`(EX2001), establish that there is good cause to admit Mr. Johnson pro hac vice in
`
`this proceeding under 37 C.F.R. § 42.10(c). Patent Owner’s Lead Counsel, Jeffrey
`
`
`
`3
`
`
`
`IPR2020-00324
`Patent 8,114,833
`
`Oelke, is a registered practitioner. Mr. Johnson is an experienced litigating
`
`attorney who has familiarity with the subject matter at issue in the proceeding.
`
`IV. CONCLUSION
`
`For all of the reasons set forth above, Patent Owner respectfully requests
`
`that the Board admit Ryan P. Johnson pro hac vice in this proceeding.
`
`Dated: February 12, 2020
`
`Respectfully submitted,
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2020-00324
`Patent 8,114,833
`
`Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing
`
`document was served on February 12, 2020, by filing this document through
`
`the Patent Trial and Appeal Board End to End System, as well as delivering a copy
`
`via electronic mail upon the following attorneys of record for the Petitioner:
`
`Brandon M. White
`Lara Dueppen
`Perkins Coie LLP
`white-ptab@perkinscoie.com
`dueppen-ptab@perkinscoie.com
`Liraglutide@perkinscoie.com
`
`Date: February 12, 2020
`
`Respectfully submitted,
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`5
`
`